An observational study in Lung, Lung Cancer and Cancer, sponsored by The First Affiliated Hospital of Guangzhou Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-01-16.
Sponsored by The First Affiliated Hospital of Guangzhou Medical University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Lung Neoplasms by The First Affiliated Hospital of Guangzhou Medical University — 20 open to participants now, 20 under way, none of them phase 3. Lung Neoplasms · The First Affiliated Hospital of Guangzhou Medical University.
Among the 26 studies in Lung Neoplasms by The First Affiliated Hospital of Guangzhou Medical University, this one is one of 2 that started in 2019, is one of 8 observational ones, reaches primary completion later than 8 of the 19 other live ones, and was the 9th registered.
5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.
Browse Lung Neoplasms studies →20 of the 26 studies in Lung Neoplasms by The First Affiliated Hospital of Guangzhou Medical University are open now, in 1 country. Recruiting first, the newest first:
The First Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 18–80
The First Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 40–74 · Healthy volunteers
The First Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 40–74 · Healthy volunteers
The First Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 18–75
The First Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 18–75
By country, each count listing its studies:
Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,500 is above the median of 200 across 1,436 observational studies indexed under Lung Neoplasms.
Median enrollment 110 across the 18 interventional studies, 550 across the 8 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
The First Affiliated Hospital of Guangzhou Medical University is the lead sponsor of 167 studies on the registry; 69 are open to participants now.
7 of the studies in Lung Neoplasms by The First Affiliated Hospital of Guangzhou Medical University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07150416The First Affiliated Hospital of Guangzhou Medical UniversityNebulized Inhalation of Recombinant Human p53 Adenovirus Injection for Treatment of Multiple Ground-Glass Lung Nodules: A Single-Arm Clinical Study | 2026-12-01 |
| NCT06778512The First Affiliated Hospital of Guangzhou Medical UniversityLcProt: Proteomics Longitudinal Cohort Study on Lung Cancer | 2026-12-01 |
| NCT06422637The First Affiliated Hospital of Guangzhou Medical UniversityA Prospective Interventional Study on Early Screening for Lung Cancer Using Liquid Biopsy | 2026-12-01 |
| NCT06843707The First Affiliated Hospital of Guangzhou Medical UniversityEstablishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics. | 2026-12-31 |
| NCT07303881The First Affiliated Hospital of Guangzhou Medical UniversityGolidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer | 2027-06 |
Add all 7 to your calendar (.ics) → With an account.
Among the 26 studies in Lung Neoplasms by The First Affiliated Hospital of Guangzhou Medical University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will utilize tissue and peripheral blood samples for proteomics analysis and establish a longitudinal proteomics cohort at multiple critical treatment time points to explore the research value of proteomics in the diagnosis and treatment of lung cancer. The study includes key time points such as screening, postoperative efficacy prediction, and efficacy prediction after medication.
Patients with lung nodules confirmed by CT examination.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
(8) Medication use before pulmonary function testing that does not meet the cessation guidelines; (9) Pulmonary function report quality graded D-F.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Peripheral blood samples from enrolled participants will be drawn, or lesion tissues will be obtained through procedures such as biopsy or surgery, followed by quantitative proteomics analysis using mass spectrometry.
Also known as: Draw peripheral blood, Obtain lesion tissue
Area Under the Curve
AUC, or Area Under the Curve, is a commonly used metric in statistical and machine learning models, particularly for evaluating the performance of classification models. It refers to the area under the Receiver Operating Characteristic (ROC) curve, which plots the true positive rate (sensitivity) against the false positive rate (1-specificity) at various threshold settings. An AUC value ranges from 0 to 1, where: * 1 indicates a perfect model, * 0.5 suggests a model no better than random guessing, * \< 0.5 reflects a model performing worse than random. In clinical studies, AUC is often used to assess diagnostic tests, where a higher AUC indicates better test accuracy in distinguishing between conditions (e.g., disease vs. no disease).
Time frame: 3 years
Differentially Expressed Proteins
Differential proteins, or differentially expressed proteins (DEPs), refer to proteins that show significant changes in expression levels between different biological or experimental conditions, such as disease vs. healthy states, treated vs. untreated groups, or across time points in longitudinal studies. These proteins are identified through quantitative proteomics techniques, including mass spectrometry or label-free methods, and analyzed using statistical or bioinformatics tools to determine significance.
Time frame: 3 years
Started Jun 2019 (actual). Primary completion is estimated for Dec 2026, 90 months after the start.
Of 592 non-industry observational studies under Lung Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 162. This study's planned 90 months is above that.
Counting every sponsor, half of 682 studies reached it within 57 months; a quarter within 25 and three quarters within 135.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The First Affiliated Hospital of Guangzhou Medical University →